Endo International

Endo Reaches Resolution with U.S. Department of Justice Regarding Legacy Marketing of Opana® ER

Retrieved on: 
Thursday, February 29, 2024

DUBLIN, Feb. 29, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that its subsidiary, Endo Health Solutions Inc. ("EHSI"), has agreed to resolve all issues regarding previously disclosed U.S. Department of Justice ("DOJ") investigations of EHSI and other Company subsidiaries related to certain legacy marketing of Opana® ER. The Company voluntarily stopped marketing Opana® ER directly to U.S. healthcare providers in 2016 and stopped selling Opana® ER in 2017.

Key Points: 
  • DUBLIN, Feb. 29, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that its subsidiary, Endo Health Solutions Inc. ("EHSI"), has agreed to resolve all issues regarding previously disclosed U.S. Department of Justice ("DOJ") investigations of EHSI and other Company subsidiaries related to certain legacy marketing of Opana® ER.
  • The Company voluntarily stopped marketing Opana® ER directly to U.S. healthcare providers in 2016 and stopped selling Opana® ER in 2017.
  • EHSI also agreed to resolve the DOJ's civil investigation of the sales and marketing of Opana® ER.
  • Endo submitted the DOJ resolutions to the Bankruptcy Court for approval, which Endo is seeking in conjunction with its proposed Plan of Reorganization.

Endo Reaches Resolution with U.S. Department of Justice Regarding Legacy Marketing of Opana® ER

Retrieved on: 
Thursday, February 29, 2024

DUBLIN, Feb. 29, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that its subsidiary, Endo Health Solutions Inc. ("EHSI"), has agreed to resolve all issues regarding previously disclosed U.S. Department of Justice ("DOJ") investigations of EHSI and other Company subsidiaries related to certain legacy marketing of Opana® ER. The Company voluntarily stopped marketing Opana® ER directly to U.S. healthcare providers in 2016 and stopped selling Opana® ER in 2017.

Key Points: 
  • DUBLIN, Feb. 29, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that its subsidiary, Endo Health Solutions Inc. ("EHSI"), has agreed to resolve all issues regarding previously disclosed U.S. Department of Justice ("DOJ") investigations of EHSI and other Company subsidiaries related to certain legacy marketing of Opana® ER.
  • The Company voluntarily stopped marketing Opana® ER directly to U.S. healthcare providers in 2016 and stopped selling Opana® ER in 2017.
  • EHSI also agreed to resolve the DOJ's civil investigation of the sales and marketing of Opana® ER.
  • Endo submitted the DOJ resolutions to the Bankruptcy Court for approval, which Endo is seeking in conjunction with its proposed Plan of Reorganization.

Lazard Reports Fourth-Quarter and Full-Year 2023 Results

Retrieved on: 
Thursday, February 1, 2024

Operating revenue was $761 million for the fourth quarter of 2023, 13% higher than the fourth quarter of 2022, and $2,440 million for 2023, 12% lower than 2022.

Key Points: 
  • Operating revenue was $761 million for the fourth quarter of 2023, 13% higher than the fourth quarter of 2022, and $2,440 million for 2023, 12% lower than 2022.
  • For the fourth quarter of 2023, Asset Management operating revenue was $274 million, 6% higher than the fourth quarter of 2022.
  • Effective January 1, 2024, Lazard completed its conversion to a U.S. C-Corporation and changed its name from Lazard Ltd to Lazard, Inc.
  • ET on February 1, 2024, to discuss the company’s financial results for the fourth quarter and full year of 2023.

Endo Announces Publication of New XIAFLEX® (collagenase clostridium histolyticum) Survey Data in Journal of Hand Surgery Global Open

Retrieved on: 
Wednesday, January 24, 2024

DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study .1

Key Points: 
  • DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study .1
    Consensus-based study findings among expert hand surgeons indicate that XIAFLEX® (collagenase clostridium histolyticum) has a wide-ranging application for the appropriate treatment of Dupuytren's contracture in patients with varying degrees of disease severity and functional impairment.
  • Results from the published research indicate a high level of consensus for using XIAFLEX for the treatment of one- or two-finger metacarpophalangeal (MP) joint contractures, most one- or two-finger proximal interphalangeal (PIP) joint contractures, and most combined MP and PIP joint contractures.
  • "Healthcare providers and patients can choose among multiple surgical and nonsurgical treatment options for Dupuytren's disease, and without established guidelines, the process for sorting through those choices can be overwhelming," said Dr. Gary M. Pess, a hand and upper extremity surgeon and lead author of the study.
  • "This study provides insight from experienced hand surgeons about using XIAFLEX to treat varying degrees of Dupuytren's contracture."

Endo Announces Publication of New XIAFLEX® (collagenase clostridium histolyticum) Survey Data in Journal of Hand Surgery Global Open

Retrieved on: 
Wednesday, January 24, 2024

DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study .1

Key Points: 
  • DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study .1
    Consensus-based study findings among expert hand surgeons indicate that XIAFLEX® (collagenase clostridium histolyticum) has a wide-ranging application for the appropriate treatment of Dupuytren's contracture in patients with varying degrees of disease severity and functional impairment.
  • Results from the published research indicate a high level of consensus for using XIAFLEX for the treatment of one- or two-finger metacarpophalangeal (MP) joint contractures, most one- or two-finger proximal interphalangeal (PIP) joint contractures, and most combined MP and PIP joint contractures.
  • "Healthcare providers and patients can choose among multiple surgical and nonsurgical treatment options for Dupuytren's disease, and without established guidelines, the process for sorting through those choices can be overwhelming," said Dr. Gary M. Pess, a hand and upper extremity surgeon and lead author of the study.
  • "This study provides insight from experienced hand surgeons about using XIAFLEX to treat varying degrees of Dupuytren's contracture."

Endo's Paladin Labs Announces Launch of XCOPRI® (cenobamate tablets) in Canada

Retrieved on: 
Monday, January 22, 2024

MONTREAL, Jan. 22, 2024 /PRNewswire/ -- Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI® (cenobamate tablets) is now available in Canada.

Key Points: 
  • MONTREAL, Jan. 22, 2024 /PRNewswire/ -- Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI® (cenobamate tablets) is now available in Canada.
  • XCOPRI is indicated as adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.
  • "We are pleased to announce the availability of XCOPRI in Canada," said Livio Di Francesco, Vice President & General Manager of Paladin Labs Inc. "As a company dedicated to addressing unmet medical needs, we are committed to supporting the ongoing innovation in epilepsy management."
  • Paladin Labs continues to work with federal, provincial, and territorial government payers across Canada and their negotiating body, the pan-Canadian Pharmaceutical Alliance, to help appropriate patients gain access to XCOPRI as soon as possible.

Endo's Paladin Labs Announces Launch of XCOPRI® (cenobamate tablets) in Canada

Retrieved on: 
Monday, January 22, 2024

MONTREAL, Jan. 22, 2024 /PRNewswire/ -- Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI® (cenobamate tablets) is now available in Canada.

Key Points: 
  • MONTREAL, Jan. 22, 2024 /PRNewswire/ -- Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI® (cenobamate tablets) is now available in Canada.
  • XCOPRI is indicated as adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.
  • "We are pleased to announce the availability of XCOPRI in Canada," said Livio Di Francesco, Vice President & General Manager of Paladin Labs Inc. "As a company dedicated to addressing unmet medical needs, we are committed to supporting the ongoing innovation in epilepsy management."
  • Paladin Labs continues to work with federal, provincial, and territorial government payers across Canada and their negotiating body, the pan-Canadian Pharmaceutical Alliance, to help appropriate patients gain access to XCOPRI as soon as possible.

Endo Announces New Data for Dupuytren's Contracture Presented at the American Association for Hand Surgery Annual Meeting

Retrieved on: 
Friday, January 19, 2024

DUBLIN, Jan. 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that two new presentations related to Dupuytren's contracture and XIAFLEX® (collagenase clostridium histolyticum) were shared during the American Association for Hand Surgery (AAHS) annual meeting.

Key Points: 
  • DUBLIN, Jan. 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that two new presentations related to Dupuytren's contracture and XIAFLEX® (collagenase clostridium histolyticum) were shared during the American Association for Hand Surgery (AAHS) annual meeting.
  • Endo provided funding through an investigator-initiated research grant.
  • "This medical knowledge presented at the AAHS annual meeting may help healthcare providers treat patients with Dupuytren's contracture and, hopefully, improve patient outcomes," said Dr. Jason Nydick, an orthopedic hand surgeon at Florida Orthopaedic Institute in Tampa, Florida and lead investigator of the studies.
  • "The results related to the effective treatment of the proximal interphalangeal (PIP) joint with XIAFLEX are particularly noteworthy."

Endo Announces New Data for Dupuytren's Contracture Presented at the American Association for Hand Surgery Annual Meeting

Retrieved on: 
Friday, January 19, 2024

DUBLIN, Jan. 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that two new presentations related to Dupuytren's contracture and XIAFLEX® (collagenase clostridium histolyticum) were shared during the American Association for Hand Surgery (AAHS) annual meeting.

Key Points: 
  • DUBLIN, Jan. 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that two new presentations related to Dupuytren's contracture and XIAFLEX® (collagenase clostridium histolyticum) were shared during the American Association for Hand Surgery (AAHS) annual meeting.
  • Endo provided funding through an investigator-initiated research grant.
  • "This medical knowledge presented at the AAHS annual meeting may help healthcare providers treat patients with Dupuytren's contracture and, hopefully, improve patient outcomes," said Dr. Jason Nydick, an orthopedic hand surgeon at Florida Orthopaedic Institute in Tampa, Florida and lead investigator of the studies.
  • "The results related to the effective treatment of the proximal interphalangeal (PIP) joint with XIAFLEX are particularly noteworthy."

miraDry® Appoints Medical Aesthetic Leaders Amber Edwards as Chair and Robert Catlin as New Chief Executive Officer

Retrieved on: 
Tuesday, January 16, 2024

NEWPORT BEACH, Calif., Jan. 16, 2024 /PRNewswire/ -- miraDry, the global medical device leader in underarm sweat and odor treatment, announces Amber Edwards as newly appointed Chair and Robert Catlin, former SVP and General Manager of Endo Aesthetics, as Chief Executive Officer. Arash Khazei will step down as Chief Executive Officer, continuing in the near term as a strategic advisor to the company. Together Ms. Edwards and Mr. Catlin bring a wealth of experience in global commercial excellence, positioning miraDry for significant expansion.

Key Points: 
  • NEWPORT BEACH, Calif., Jan. 16, 2024 /PRNewswire/ -- miraDry, the global medical device leader in underarm sweat and odor treatment, announces Amber Edwards as newly appointed Chair and Robert Catlin, former SVP and General Manager of Endo Aesthetics, as Chief Executive Officer.
  • Arash Khazei will step down as Chief Executive Officer, continuing in the near term as a strategic advisor to the company.
  • Together Ms. Edwards and Mr. Catlin bring a wealth of experience in global commercial excellence, positioning miraDry for significant expansion.
  • "We are thrilled to have Rob Catlin join this dynamic team bringing broad commercial leadership experience in dermatologic and aesthetic categories.